Pomegranate ellagitannins

Herbal Medicine: Biomolecular and Clinical Aspects: Second Edition

Volumn , Issue , 2011, Pages 201-209

  Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85020903136     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Adams, L. S., N. P. Seeram, B. B. Aggarwal, Y. Takada, D. Sand, and D. Heber. 2006. Pomegranate juice, total pomegranate tannins and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 54:980-5.
2. Adams, L. S., Y. Zhang, N. P. Seeram, D. Heber, and S. Chen. 2010. Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res (Phila Pa) 3:108-13.
3. Afaq, F., M. Saleem, C. G. Krueger, J. D. Reed, and H. Mukhtar. 2005. Anthocyanin- and hydrolysable tanninrich pomegranate fruit extract modulates MAPK and NF-κB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer 113:423-33.
4. Albrecht, M., W. Jiang, J. Kumi-Diaka et al. 2004. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 7:274-83.
5. Allison, A. C. 1997. Antioxidant drug targeting. Adv Pharmacol 38:273-91.
6. Amakura, Y., M. Okada, T. Sumiko, and Y. Tonogai. 2000. High-performance liquid chromatographic determination with photodiode array detection of ellagic acid in fresh and processed fruits. J Chromatogr A 896:87-93.
7. Aronson, W., R. Barnard, S. Freedland, S. Henning, D. Elashoff, P. Jardack, P. Cohen, D. Heber, and N. Kobayashi. 2010. Growth inhibitory effect of low-fat diet on prostate cancer cells: Results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol 183:345-50.
8. Biswas, D. K., A. P. Curz, E. Gansberger, and A. B. Pardee. 2000. Epidermal growth factor-induced nuclear factor kappaB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97:8542-7.
9. Castonguay, A., H. U. Gali, E. M. Perchellet et al. 1997. Antitumorigenic and antipromoting activities of ellagic acid, ellagitannins and oligomeric anthocyanin and procyanidin. Int J Oncol 10:367-73.
10. Cerda, B., J. C. EspÌn, S. Parra, P. MartÌnez, and F. A. Tom•s-Barber•n. 2004. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr 43:205-20.
11. Cerda, B., R. Llorach, J. J. Cerón, J. C. Espín, and F. A. Tomás-Barberán. 2003. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 42:18-28.
12. Clifford, M. N., and A. Scalbert. 2000. Ellagitannins-nature, occurrence and dietary burden. J Sci Food Agric 80:1118-25.
13. Conner, E. M., and M. B. Grisham. 1996. Inflammation, free radicals and antioxidants. Nutrition 12:274-7.
14. De Marzo, A. M., A. K. Meeker, S. Zha, J. Luo, M. Nakayama, and E. A. Platz. 2003. Human prostate cancer precursors and pathobiology. Urology 62:55-62.
15. Domingo-Domenech, J., B. Mellado, B. Ferrer et al. 2005. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93:1285-94.
16. Espin, J. C., R. González-Barrio, B. Cerdá, C. López-Bote, A. I. Rey, and F. A. Tomás-Barberán. 2007. Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 55:10476-85.
17. Fradet, L., L. R. Bégin, P. Karakiewicz, A. M. Masson, and F. Saad. 2004. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10:8460-4.
18. Gasparian, A. V., Y. J. Yao, D. Kowalczyk et al. 2002. The role of IKK in constitutive activation of NF-kappaB in pancreatic carcinoma cells. J Cell Sci 155:141-51.
19. Gil, M. I., F. A. Tomás-Barberán, B. Hess-Pierce, D. M. Holcroft, and A. A. Kader. 2000. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 48:4581-9.
20. Hong, M. Y., N. P. Seeram, and D. Heber. 2008. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem 19:848-55.
21. Kim, D. W., M. A. Sovak, and G. Zanieski. 2000. Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21:871-9.
22. Koyama, S., L. J. Cobb, H. H. Mehta, N. P. Seeram, D. Heber, A. J. Pantuck, and P. Cohen. 2010. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res 20:55-62.
23. Lansky, E. P., W. Jiang, H. Mo et al. 2005. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs 23:11-20.
24. Larrosa, M., F. A. Tomás-Barberán, and J. C. Espin. 2006. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem 17:611-25.
25. Longtin, R. 2003. The pomegranate: Nature's power fruit? J Natl Cancer Inst 95:346-8.
26. Losso, J. N., R. R. Bansode, A. Trappey, A. A. Bawadi, and R. Truax. 2004. In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem 15:672-8.
27. Malik, A., F. Afaq, S. Sarfaraz, V. M. Adhami, D. N. Syed, and H. Mukhtar. 2005. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102:14813-8.
28. Mayo, M. W., and A. S. Baldwin. 2000. The transcription factor NF-kappaB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470:M55-62.
29. Narayanan, B. A., O. Geoffroy, M. C. Willingham, G. G. Re, and D. W. Nixon. 1999. p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett 136:215-21.
30. O'Byrne, K. J., and A. G. Dalgleish. 2001. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85:473-83.
31. Palayoor, S. T., M. Y. Youmell, S. K. Claderwood, C. N. Coleman, and B. D. Price. 1999. Constitutive activation of IkB kinase a and NFκB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18:7389-94.
32. Pantuck, A. J., J. T. Leppert, N. Zomorodian et al. 2006. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12:4018-26.
33. Rayet, B., and C. Gelinas. 1999. Aberrant rel/nfκb genes and activity in human cancer. Oncogene 18:6938-45.
34. Rettig, M. B., D. Heber, N. P. Seeram et al. 2008. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther 7:2662-71.
35. Sartippour, M. R., N. P. Seeram, J. Y. Rao, A. Moro, D. M. Harris, S. M. Henning, and D. Heber. 2008. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 32:475-80.
36. Seeram, N. P., L. S. Adams, S. M. Henning, Y. Niu, Y. Zhang, M. G. Nair, and D. Heber. 2005. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 16:360-7.
37. Seeram, N. P., W. J. Aronson, Y. Zhang, S. M. Henning, A. Moro, R. P. Lee, and D. Heber. 2007. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 55:7732-7.
38. Seeram, N. P., M. Aviram, Y. Zhang, S. M. Henning, L. Feng, M. Dreher, and D. Heber. 2008. Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J Agric Food Chem 56:1415-22.
39. Seeram, N. P., S. M. Henning, Y. Zhang, M. Suchard, Z. Li, and D. Heber. 2006. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 136:2481-5.
40. Seeram, N. P., R. Lee, and D. Heber. 2004. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 348:63-8.
41. Seeram, N. P., R. N. Schulman, and D. Heber. 2006. Pomegranates: Ancient Roots to Modern Medicine. Boca Raton, FL: CRC Press.
42. Seeram, N. P., Y. Zhang, R. McKeever et al. 2008. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food 11:390-4
43. Suh, J., F. Payvandi, L. Edelstein et al. 2002. Mechanisms of constitutive NFκB activation in human prostate cancer cells. Prostate 52:183-200.
44. Winyard, P. G., and D. R. Blake. 1997. Antioxidants, redox-regulated transcription factors and inflammation. Adv Pharmacol 38:403-21.